AQT90 FLEX NTproBNP2 Test Kit - 23004 - Reference Interval Study

Last updated: August 1, 2025
Sponsor: Radiometer Medical ApS
Overall Status: Completed

Phase

N/A

Condition

Heart Failure

Chest Pain

Congestive Heart Failure

Treatment

No intervention; Observational study

Clinical Study ID

NCT06834880
DC-087455
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to establish the overall (age- and sex independent) at least 95th percentile upper reference limit (URL) of the NTproBNP2 Test Kit on the AQT90 FLEX analyzer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subject must have given their valid consent to donate their sample in the samplebank

  • Subjects must have been 18 years of age or older at the time of sample collection

  • Subject must have answered yes, to being generally healthy, in the healthquestionnaire

  • Subjects must, as a minimum, have completed questions regarding age, gender, race,and ethnicity

Exclusion

Exclusion Criteria:

Answered yes to any of the conditions below (Information gathered from a self-reported health questionnaire or results from blood sample tests):

  • Current medications for treating cardiovascular diseases at the time of samplecollection

  • Current antibiotics (Indicates ongoing infections)

  • Known to suffer from any of the illnesses below at the time of sample collection:

  • Disease(s) of/or affecting the cardiovascular system

  • Congestive heart failure

  • Hypertension

  • Previous history of any heart disease

  • Diabetes (Either self-reported in questionnaire or a glycosylated hemoglobin (HbA1C) in the diabetic range (above 6.4%)

  • Renal dysfunction or failure (An estimated glomerular filtration rate (eGFR)below 60 mL/min/1.73m2.) This is to be calculated using information on age, sexand creatinine using the 2021 chronic kidney disease epidemiology (CKD-EPI)creatinine equation.

  • Cancer or history of cancer

Study Design

Total Participants: 781
Treatment Group(s): 1
Primary Treatment: No intervention; Observational study
Phase:
Study Start date:
January 27, 2025
Estimated Completion Date:
February 05, 2025

Study Description

The NTproBNP2 Test is an in vitro diagnostic assay for the quantitative determination of N-terminal pro-B-type natriuretic peptide {NT-proBNP) in EDTA or lithium heparin whole blood or plasma specimens on the AQT90 FLEX analyzer in point of care/ near-patient testing and laboratory settings. It is intended for use as an aid in the diagnosis of heart failure. The test is also intended for use as an aid in the risk stratification of patients with acute coronary syndrome and heart failure.

The NTproBNP2 CAL Cartridge is an in vitro diagnostic reagent intended for the calibration adjustment of the NTproBNP2 Test on the AQT90 FLEX analyzer by establishing points of reference to estimate NT-proBNP values.

The AQT90 FLEX analyzer is an immunoassay instrument based on the quantitative determination of time-resolved fluorescence to estimate the concentrations of clinically relevant markers on whole-blood and plasma specimens to which a relevant anticoagulant has been added. It is intended for use in point of care/ near-patient testing and laboratory settings.

Connect with a study center

  • Radiometer Turku Oy

    Turku, 20750
    Finland

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.